2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea

Shane, Andi L.; Mody, Rajal K.; Crump, John A.; Tarr, Phillip I.; Steiner, Theodore S.; Kotloff, Karen L.; Langley, Joanne M.; Wanke, Christine; Warren, Cirle A.; Cheng, Allen; Cantey, J. Robert; Pickering, Larry K.

doi:10.1093/cid/cix669

Cited by 377 publications

(341 citation statements)

References 188 publications

Supporting

Mentioning

304

Contrasting

Unclassified

Order By: Relevance

“…It also accounts for a substantial number of out‐patient or emergency department visits and hospitalisations. Oral rehydration therapy is the mainstay of treatment for acute gastroenteritis and should be applied promptly . However, despite proven efficacy, oral rehydration remains underused.…”

Section: Introductionmentioning

confidence: 99%

“…However, despite proven efficacy, oral rehydration remains underused. Several guidelines recommend using probiotics with proven efficacy and safety for the management of children with acute gastroenteritis as an adjunct to rehydration therapy . Two strains most commonly recommended are Lactobacillus rhamnosus GG ( L rhamnosus GG) and Saccharomyces boulardii ( S boulardii ) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review with meta‐analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update

Szajewska

Kołodziej

Zalewski

2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background There is still controversy with regard to the efficacy of individual probiotic strains for the management of acute gastroenteritis. Aim To update evidence on use of Saccharomyces boulardii for treating acute gastroenteritis in children. Methods The Cochrane Library, MEDLINE and EMBASE databases were searched from inception to December 2019 for randomised controlled trials (RCTs) that compared use of S boulardii with no S boulardii (defined as placebo or no treatment). The grey literature was searched through Google search. Authors of the original papers and S boulardii manufacturers were contacted for additional data. Results Twenty‐nine RCTs (among them, 20 newly identified trials) were included. Only 38% of trials adequately generated their randomisation sequence, only 17% adequately concealed allocation and only one trial adequately blinded participants, study personnel and outcome assessors. However, 83% provided complete outcome data. None of the trials evaluated the effect of S boulardii on stool volume. Compared with placebo or no treatment, S boulardii use reduced the duration of diarrhoea (23 RCTs, n = 3450, mean difference −1.06 day, 95% CI −1.32 to −0.79; high heterogeneity [I2 = 90%]) (very low quality of evidence). S boulardii use was also associated with a reduced duration of hospitalisation (8 RCTs, n = 999, mean difference −0.85 day, 95% CI −1.35 to −0.34; I2 = 91%) (very low quality of evidence). S boulardii reduced the risk of diarrhoea on day 2 to day 7 (low quality of evidence). Conclusions In children with acute gastroenteritis, low‐ to very low‐quality evidence suggests that S boulardii confers a benefit for several diarrhoeal outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Systematic review with meta‐analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update

Szajewska

Kołodziej

Zalewski

2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…It is recommended that treatment for life-threatening infections should include both a quinolone and a 3GC, until susceptibilities are known and focused treatment can be initiated [103]. In children and pregnant women, treatment with quinolones is relatively contra-indicated, limiting treatment options to 3GC [12]. Ceftriaxone is the treatment of choice for Salmonella infection of the meninges, the central nervous system or infective endocarditis, due to its ability to penetrate the blood–brain barrier and cardiac vegetations and devitalised tissue [104].…”

Section: Results (Headings As Per the Codex Guidelines)mentioning

confidence: 99%

“…Alternative treatment choices are directed by the site of infection, causative bacteria, susceptibility testing, patient hypersensitivity and severity of infection. The Infectious Diseases Society of America recommends ciprofloxacin, trimethoprim-sulfamethoxazole or amoxicillin (when antimicrobial treatment is indicated) as treatment alternatives for gastroenteritis caused by NTS [12]. Other alternatives, especially for extra-intestinal infections, include monobactams (aztreonam) and carbapenems [12], both of which are considered critically important for human medicine [8].…”

Section: Results (Headings As Per the Codex Guidelines)mentioning

confidence: 99%

“…The Infectious Diseases Society of America recommends ciprofloxacin, trimethoprim-sulfamethoxazole or amoxicillin (when antimicrobial treatment is indicated) as treatment alternatives for gastroenteritis caused by NTS [12]. Other alternatives, especially for extra-intestinal infections, include monobactams (aztreonam) and carbapenems [12], both of which are considered critically important for human medicine [8]. Carbapenems may be the last drug of choice for invasive Salmonella infections that are resistant to ciprofloxacin and ceftriaxone [111].…”

Section: Results (Headings As Per the Codex Guidelines)mentioning

confidence: 99%

See 1 more Smart Citation

Ceftiofur-resistant Salmonella enterica serovar Heidelberg of poultry origin – a risk profile using the Codex framework

Carson

Agunos

et al. 2019

Epidemiol. Infect.

View full text Add to dashboard Cite

Codex published the ‘Guidelines for Risk Analysis of Foodborne Antimicrobial Resistance’ to standardise the approach for evaluating risk posed by foodborne antimicrobial-resistant bacteria. One of the first steps in the guidelines is to compile a risk profile, which provides the current state of knowledge regarding a food safety issue, describes risk management options and recommends next steps. In Canada, ceftiofur/ceftriaxone-resistant Salmonella enterica subsp. enterica serovar Heidelberg from poultry was identified as an antimicrobial resistance (AMR) food safety issue. The first objective of this article was to contextualise this food safety issue, using the risk profile format of the Codex Guidelines. A second objective was to evaluate the applicability of the Codex Guidelines. This risk profile indicated that ceftiofur/ceftriaxone-resistant S. Heidelberg (CSH) was commonly isolated from poultry and was associated with severe disease in humans. Ceftiofur use in poultry hatcheries temporally mirrored the prevalence of CSH from poultry meat at retail and from people with salmonellosis. The evidence was sufficient to indicate the need for risk management options, such as restricting the use of ceftiofur in poultry. The Codex Guidelines provided a useful approach to summarise data for decision-makers to evaluate an AMR food safety issue.

show abstract

Diagnosis and Management of Infectious Diarrhea

Hamilton

Cifu

2019

JAMA

View full text Add to dashboard Cite

2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea

Cited by 377 publications

References 188 publications

Systematic review with meta‐analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update

Systematic review with meta‐analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update

Ceftiofur-resistant Salmonella enterica serovar Heidelberg of poultry origin – a risk profile using the Codex framework

Diagnosis and Management of Infectious Diarrhea

Contact Info

Product

Resources

About